Login to Your Account



Making music with MIT tech

Flu fighters: $46.7M rocks Visterra, pieces of APRIL key in nephropathy bid

By Randy Osborne
Staff Writer

Friday, October 6, 2017

"Nobody has done this before," Visterra Inc. CEO Brian Pereira told BioWorld, talking about the company's approach in immunoglobulin A (IgA) nephropathy, an effort that is part of what fueled his company's just-finished $46.7 million series C financing. Using computational tools and methods from the Massachusetts Institute of Technology, Visterra is "not an antibody discovery company," he said. "We design and engineer novel antibody-based solutions" that include monoclonal antibodies (MAbs), bispecific antibodies and antibody-drug conjugates (ADCs).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription